

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

A Facile and Practical One-Pot Synthesis of [1,2,4]triazolo[4,3-*a*]pyridines

Kamlesh S. Vadagaonkar,[†] Kaliyappan Murugan,[‡] Atul C. Chaskar,^{†*} Prakash M. Bhate^{†*}

[†]Department of Dyestuff Technology, Institute of Chemical Technology, Mumbai 400019, India

[‡]National Taiwan University, Taipei 10617, Taiwan

Tel.: +91-22- 3361 1111/ 2707; Fax: +91-22- 3361 1020;

E-mail: pm.bhate@ictmumbai.edu.in, achaskar25@gmail.com

Abstract:

A mild, efficient and operationally simple one-pot synthesis of substituted [1,2,4]triazolo[4,3-*a*]pyridines at room temperature from easily available 2-hydrazinopyridine and substituted aromatic aldehydes has been developed. This functional group tolerant and atom-economic method provides facile access to synthetically and biologically important triazolopyridine derivatives.

Introduction:

The triazolopyridine scaffold is present in several heterocyclic compounds¹ that possess a broad spectrum of biological and pharmaceutical activities, such as herbicidal, antifungal, anticonvulsant, anxiolytic, antibacterial, antithrombotic, anti-inflammatory and antiproliferative.²⁻⁵


In view of the importance of triazolopyridines in pharmacology and functional materials, a ready access to libraries of these derivatives is highly desirable. On the background of aforementioned applications of triazolopyridine derivatives, numerous methods have been developed for its synthesis. Along with 2-hydrazinopyridine either aldehyde or acid is often employed as a precursor in presence of reagents such as phosphorous oxychloride,⁶ lead tetraacetate,⁷ bromine,⁸ PS-PPh₃/CCl₄ under microwave,⁹ (diacetoxy)iodobenzene,^{3a} bis(trifluoroacetoxy) iodobenzene¹⁰ etc. In addition to this acylation of 2-hydrazinopyridine followed by dehydrative cyclization is also widely used method for synthesis of 1,2,4-triazolo[4,3-*a*]pyridines.¹¹

Since large scale synthesis is concerned, besides potential utility the aforementioned methods are associated with some shortcomings such as use of harsh reaction condition, toxic reagents,

high temperature, longer reaction time, high equivalent of the reagents and formation of large amount of toxic by-products.


Recently Schmidt *et al.* synthesized triazolopyridines from 2-hydrazinopyridine and imidates under mild condition at 50-70 °C by using 1.5 equiv. of acetic acid, wherein the reaction rate is governed by electronic and steric properties of the hydrazine and imidate moieties.¹² Thiel *et al.*¹³ synthesized triazolopyridines from 2-chloropyridine and aldehyde hydrazones, in a two step protocol involving Pd catalyzed intermolecular coupling followed by oxidative cyclization with chloramine T. The use of expensive palladium catalyst and basic aqueous work up to remove the toluenesulfonamide formed during the course of the reaction limits the use of this method for large scale synthesis. Reichelt and co-workers¹⁴ accomplished the synthesis of triazolopyridines by using acid hydrazide and 2-chloropyridine. They used palladium catalyst along with an array of phosphine ligands for the reaction of acid hydrazide with 2-chloropyridine followed by dehydrative cyclization in acetic acid under microwave irradiation.

In continuation with our interest in the development of environment friendly protocols for the synthesis of heterocyclic compounds,¹⁵⁻¹⁸ we envisaged to access pharmaceutically important triazolopyridine derivatives. In this context, herein we report the synthesis of triazolopyridines by using such reagents as *N*-bromosuccinimide (NBS)-1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), trichloroisocyanuric acid (TCCA) and hydroxy(tosyloxy)iodobenzene (HTIB) at room temperature.



Scheme 1. Synthesis of 1,2,4-triazolo[4,3-*a*]pyridine derivatives.

Table 1. Optimization of reaction conditions for one-pot oxidative cyclization of benzaldehyde with 2-hydrazinopyridine^a



Entry	^b Reagent	^c Oxidant	Temp. (°C)	Time (min)	^d Yield (%)
1)	NBS	-	RT	10	57
2)	NBS	TBHP	RT	10	62
3)	NBS	Oxone	RT	10	65
4)	NBS	DMP	RT	10	71
5)	NBS-DBU	-	RT	10	92
6)	I ₂	-	RT	120	15
7)	I ₂	TBHP	RT	120	29
8)	I ₂	TBHP	80	10	45
9)	I ₂	TBHP	80	120	72
10)	I ₂	Oxone	RT	120	35
11)	I ₂	Oxone	80	10	52
12)	I ₂	Oxone	80	120	76
13)	I ₂	DMP	RT	10	48
14)	I ₂ -DBU	-	RT	10	67
15)	KI	Oxone	RT	120	18
16)	TBAI	Oxone	RT	120	28
17)	TCCA	-	RT	10	85
18)	HTIB	-	RT	10	90

^aReaction conditions: 2-hydrazinopyridine **1** (1.0 equiv.), benzaldehyde **2a** (1.0 equiv.), ^breagent (1.0 equiv.) and ^coxidant (1.0 equiv.) in EtOH for 10-120 min. at RT-80 °C temp. ^dIsolated yields.


In order to optimize reaction conditions for the one-pot oxidative cyclization we selected the reaction between 2-hydrazinopyridine and benzaldehyde as a model. Initially, these two substrates were heated in EtOH at reflux temperature for 20 minutes. After the completion of the reaction, as indicated by TLC, the reaction mass was cooled to room temperature to afford the heterocyclic hydrazone **3a**. Different reagents were then added separately to this reaction mass at room temperature and resulting mixture was stirred for appropriate time. When 1.0 equiv. *N*-bromosuccinimide (Table 1, entry 1) was used, triazolopyridine **4a** was obtained in 57% yield in 10 minutes. We screened different oxidants such as TBHP, Oxone and DMP in combination with













N-bromosuccinimide (Table 1, entries 2-4) and were pleasantly surprised when we obtained **4a** in 92% yield in presence of 1.0 equiv. of NBS and 1.0 equiv. DBU (Table 1, entry 5). The reaction with DMP as an oxidant afforded a moderate yield of 71% while reactions by using oxone and TBHP resulted in slightly lower yields of 65 and 62%, respectively.













When 1.0 equiv. of iodine was used as a reagent at room temperature the reaction did not proceed to completion even after 120 minutes and gave only 15% yield (Table 1, entry 6). Use of TBHP (1.0 equiv.) as an oxidant at room temperature resulted in 29% yield with prolonged reaction time (Table 1, entry 7). When the reaction temperature was increased to 80 °C, 72% yield was obtained (Table 1, entry 9) in 120 minutes. The reaction was incomplete when oxone was the oxidant at room temperature, whereas yields of 52% and 76% were obtained when the reaction was carried out at 80 °C for 10 and 120 minutes, respectively (Table 1, entries 11 and 12). A moderate yield of 48% was obtained when DMP was used as an oxidant (Table 1, entry 13). Use of DBU afforded a yield of 67% (Table 1, entry 14). The combination of KI and TBAI with oxone at room temperature resulted in very low yields (Table 1, entries 15 and 16).









A high yield of 85% was obtained in 10 minutes (Table 1, entry 17) when we carried out this reaction in presence of trichloroisocyanuric acid (TCCA) at room temperature. We also tried this reaction by using hydroxy(tosyloxy)iodobenzene (HTIB) and obtained a yield of 90% at room temperature in 10 minutes (Table 1, entry 18). We conclude from Table 1 that the use of 1.0 equiv. of NBS-DBU/ TCCA/ HTIB separately at room temperature affords 1,2,4-triazolo[4,3-*a*]pyridine derivatives *via* a one-pot oxidative cyclization of heterocyclic hydrazone, formed by the condensation of 2-hydrazinopyridine and benzaldehyde in EtOH.

Table 2. Synthesis of 1,2,4-triazolo[4,3-*a*]pyridine derivatives *via* one-pot oxidative cyclization of various aldehydes with 2-hydrazinopyridine^a



Entry	Substrate	Product	^c Yield (%)		
			^b NBS-DBU	^b TCCA	^b HTIB
1	 2a	 4a	92	85	90
2	 2b	 4b	87	81	85
3	 2c	 4c	90	84	88
4	 2d	 4d	88	83	86
5	 2e	 4e	89	84	87
6	 2f	 4f	94	88	92

7	 2g	 4g	90	85	87
8	 2h	 4h	85	80	82
9	 2i	 4i	86	80	83
10	 2j	 4j	88	82	86
11	 2k	 4k	83	78	80
12	 2l	 4l	94	89	93

13	 2m	 4m	88	82	85
14	 2n	 4n	89	84	87
15	 2o	 4o	87	82	86
16	 2p	 4p	85	81	85

^aReaction conditions: 2-hydrazinopyridine **1** (1.0 equiv.), substituted aromatic aldehyde **2** (1.0 equiv.), ^breagent (1.0 equiv.) in EtOH at RT. ^cIsolated yields.

With optimized conditions in hand, we next investigated the scope and limitation of this one-pot oxidative cyclization by using different aromatic aldehydes (Table 2). The yields obtained by using all the three reagents were found to be more or less the same. The reaction is robust and is not affected by nature of substituents.

The aldehydes bearing halogen substituents at the ortho position of the formyl group (**2b**, **2c** and **2h**) due to steric hindrance resulted in slightly lower yields of products as compared to halogen groups present at the meta and para positions (**2d-2g**). When the aldehydes bearing electron donating methoxy substituent at the ortho, meta and para positions with respect to the formyl group were subjected for oxidative cyclization, the reactivity order of $m > o > p$ was

observed. The proof of concept is the excellent yield of 88% for aldehyde **2m** with *m*-phenoxy substituent. Further the aldehydes **2n-2p** bearing electron donating groups such as -OH, -NMe₂, NEt₂ at the ortho and para position of formyl group resulted in good to excellent yields (81-89%) of the products **4n-4p** by using all the three reagents. Albeit, the aldehyde **2l** bearing an electron withdrawing NO₂ substituent gave best yield due to the enhanced electrophilicity of carbonyl group.

Experimental section

General information

Chemical reagents were obtained from commercial companies. All reactions were performed in a round bottom flask and monitored by TLC performed on aluminum plates (0.25 mm, E. Merck) precoated with silica gel Merck 60 F-254. Developed TLC plates were visualized under a short-wavelength UV lamp. Yields refer to spectroscopically (¹H, ¹³C NMR) homogeneous material obtained after column chromatography performed on silica gel (100–200 mesh size) supplied by S. D. Fine Chemicals Limited, India. ¹H and ¹³C NMR spectra were recorded on Brüker 400 and Varian 300 MHz spectrometers by using tetramethylsilane (TMS) as an internal standard. Coupling constants (*J*) were measured in Hertz. All chemical shifts are quoted in ppm, relative to CDCl₃, by using the residual solvent peak as a reference standard. The number of protons (*n*) for a given resonance is indicated by *n*H. High resolution mass spectra (HRMS) were obtained by using positive electrospray ionization (ESI) by Time of Flight (TOF) method. Melting points were recorded on a standard melting point apparatus from Sunder Industrial Product, Mumbai and are uncorrected.

General procedure for one-pot oxidative cyclization:

A mixture of 2-hydrazinopyridine **1** (1.0 mmol), substituted aromatic aldehyde **2** (1.0 mmol) and EtOH (5 mL) was boiled under reflux for 20 minutes to afford the corresponding heterocyclic hydrazone **3**. The reaction mixture was cooled to room temperature and to it was added NBS (1.0 mmol) and DBU (1.0 mmol)/ TCCA (1.0 mmol)/ HTIB (1.0 mmol). The resulting mixture was stirred at room temperature for 10 minutes. After completion of reaction, as indicated by TLC, the EtOH was evaporated under vacuum. Water (10 mL) was added and the mixture extracted with DCM (2 × 10 mL). The combined organic layer was washed successively with 10% sodium

bicarbonate solution (10 mL), 10% sodium bisulphate solution (10 mL) and water (10 mL). The organic layer obtained was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to give crude product which was purified with column chromatography on 100:200 mesh silica gel by using 5% MeOH in DCM as the eluent to afford the pure product **4**.

Product characterization

3-Phenyl-[1,2,4]triazolo[4,3-*a*]pyridine (4a). White solid; MP 172-174 °C; ¹H NMR (400 MHz, CDCl₃): δ = 6.86 (t, *J* = 6.8 Hz, 1H), 7.28 (t, *J* = 8.4 Hz, 1H), 7.54-7.59 (m, 3H), 7.82 (d, *J* = 7.2 Hz, 3H), 8.28 (d, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 114.29, 116.92, 122.69, 126.70, 127.15, 128.33, 129.39, 130.30, 146.95, 150.61; HRMS (ESI-MS): *m/z* [M + H]⁺ calcd for C₁₂H₁₀N₃: 196.0875; found: 196.0877.

3-(2-Chlorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4b). Off white solid; MP 124-126 °C; ¹H NMR (400 MHz, CDCl₃): δ = 6.87 (t, *J* = 6.8 Hz, 1H), 7.32 (t, *J* = 7.2 Hz, 1H), 7.48 (d, *J* = 6.8 Hz, 1H), 7.54-7.59 (m, 2H), 7.67 (d, *J* = 6.4 Hz, 1H), 7.78-7.86 (dd, *J* = 8.8, 6.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 113.90, 116.65, 123.60, 125.99, 127.43, 127.55, 130.23, 132.10, 133.38, 134.15, 145.06, 150.33; HRMS (ESI-MS): *m/z* [M + H]⁺ calcd for C₁₂H₉ClN₃: 230.0486; found: 230.0488.

3-(2-Bromophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4c). Off white solid; MP 158-160 °C; ¹H NMR (400 MHz, CDCl₃): δ = 6.87 (t, *J* = 6.4 Hz, 1H), 7.32 (t, *J* = 8.0 Hz, 1H), 7.44-7.53 (m, 2H), 7.62 (d, *J* = 7.2 Hz, 1H), 7.77 (d, *J* = 7.2 Hz, 2H), 7.85 (d, *J* = 9.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 113.87, 116.63, 123.58, 123.81, 127.44, 128.04, 128.10, 132.26, 133.42, 133.60, 146.10, 150.17; HRMS (ESI-MS): *m/z* [M + H]⁺ calcd for C₁₂H₉BrN₃: 273.9981; found: 273.9985.

3-(3-Chlorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4d). White solid; MP 160-162 °C; ¹H NMR (400 MHz, CDCl₃): δ = 6.92 (t, *J* = 6.8 Hz, 1H), 7.31 (t, *J* = 8.0 Hz, 1H), 7.51 (d, *J* = 4.4 Hz, 2H), 7.72 (d, *J* = 4.0 Hz, 1H), 7.84 (d, *J* = 5.2 Hz, 2H), 8.27 (d, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 114.73, 117.02, 122.50, 126.30, 127.43, 128.26, 128.42, 130.39, 130.72, 135.43, 145.54, 150.75; HRMS (ESI-MS): *m/z* [M + H]⁺ calcd for C₁₂H₉ClN₃: 230.0486; found: 230.0490.

3-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4e). Off white solid; MP 160-162 °C; ¹H NMR (400 MHz, CDCl₃): δ = 6.89 (t, *J* = 6.8 Hz, 1H), 7.26-7.31 (m, 3H), 7.82 (d, *J* = 8.4 Hz, 3H), 8.22 (d, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 114.49, 116.57, 116.78, 116.96, 122.44, 122.85, 122.88, 127.22, 130.35, 130.44, 145.97, 150.59; HRMS (ESI-MS): *m/z* [M + H]⁺ calcd for C₁₂H₉FN₃: 214.0781; found: 214.0785.

3-(4-Bromophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4f). Off white solid; MP 194-196 °C; ^1H NMR (400 MHz, CDCl_3): δ = 6.90 (t, J = 6.8 Hz, 1H), 7.31 (t, J = 8.8 Hz, 1H), 7.72 (s, 4H), 7.83 (d, J = 9.2 Hz, 1H), 8.24 (d, J = 6.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 114.65, 117.03, 122.47, 124.71, 125.63, 127.35, 129.70, 132.69, 145.89, 150.71; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_9\text{BrN}_3$: 273.9981; found: 273.9983.

3-(3,4-Dichlorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4g). White solid; MP 224-226 °C; ^1H NMR (400 MHz, CDCl_3): δ = 6.95 (t, J = 6.4 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.66-7.72 (q, J = 8.4, 7.2 Hz, 2H), 7.86 (d, J = 9.2 Hz, 1H), 7.96 (s, 1H), 8.25 (d, J = 6.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 114.96, 117.15, 122.33, 126.63, 127.23, 127.52, 129.90, 131.50, 133.91, 134.70, 144.71, 150.85; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_8\text{Cl}_2\text{N}_3$: 264.0096; found: 264.0098.

3-(2,6-Dichlorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4h). White solid; MP 184-186 °C; ^1H NMR (400 MHz, CDCl_3): δ = 6.88 (t, J = 6.8 Hz, 1H), 7.35 (t, J = 8.4 Hz, 1H), 7.46-7.53 (m, 3H), 7.64 (d, J = 6.8 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 114.36, 116.77, 122.64, 125.23, 127.60, 128.59, 132.73, 137.46, 142.03, 150.03; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_8\text{Cl}_2\text{N}_3$: 264.0096; found: 264.0098.

3-(2-Methoxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4i). White solid; MP 112-114 °C; ^1H NMR (400 MHz, CDCl_3): δ = 3.80 (s, 3H), 6.79 (t, J = 6.8 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.79 (d, J = 7.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ = 55.66, 111.34, 113.10, 115.56, 116.31, 121.43, 124.55, 127.08, 132.22, 132.71, 145.49, 150.38, 157.24; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}$: 226.0981; found: 226.0983.

3-(3-Methoxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4j). White solid; MP 118-120 °C; ^1H NMR (300 MHz, CDCl_3): δ = 3.88 (s, 3H), 6.86 (t, J = 6.9 Hz, 1H), 7.08 (d, J = 7.2 Hz, 1H), 7.25-7.38 (m, 3H), 7.48 (t, J = 8.1 Hz, 1H), 7.82 (d, J = 9.3 Hz, 1H), 8.31 (d, J = 7.2 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 55.58, 113.76, 114.29, 116.33, 116.87, 120.11, 122.82, 127.19, 127.86, 130.40, 146.71, 150.63, 160.30; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}$: 226.0981; found: 226.0987.

3-(4-Methoxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4k). White solid; MP 124-126 °C; ^1H NMR (400 MHz, CDCl_3): δ = 3.88 (s, 3H), 6.83 (t, J = 6.4 Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.25 (distorted t, J = 9.2, 3.2 Hz, 1H), 7.73-7.80 (m, 3H), 8.22 (d, J = 6.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 55.52, 114.09, 114.82, 116.85, 118.92, 122.67, 126.94, 129.80, 146.76, 150.42, 161.10; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}$: 226.0981; found: 226.0985.

3-(3-Nitrophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4l). Pale yellow solid; MP 288-290 °C; ^1H NMR (400 MHz, CDCl_3): δ = 7.00 (t, J = 6.8 Hz, 1H), 7.38 (t, J = 8.8 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.91 (d, J = 9.2 Hz, 1H), 8.27-8.33 (dd, J = 7.6, 6.8 Hz, 2H), 8.42 (d, J = 8.0 Hz, 1H),

8.72 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 115.30, 117.30, 122.18, 122.43, 124.87, 127.72, 128.55, 130.77, 134.34, 142.60, 145.49, 151.80$; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_9\text{N}_4\text{O}_2$: 241.0726; found: 241.0730.

3-(3-Phenoxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4m). Off white solid; MP 114-116 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 6.87$ (t, $J = 6.4$ Hz, 1H), 7.08 (d, $J = 8.0$ Hz, 2H), 7.15 (t, $J = 7.2$ Hz, 2H), 7.29 (distorted t, $J = 8.0, 7.2$ Hz, 1H), 7.37 (t, $J = 7.6$ Hz, 2H), 7.46 (s, 1H), 7.55 (s, 2H), 7.83 (d, $J = 9.2$ Hz, 1H), 8.27 (d, $J = 6.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 114.42, 116.95, 118.16, 119.50, 120.24, 122.66, 122.71, 124.14, 127.24, 128.25, 130.08, 130.83, 146.24, 150.67, 156.42, 158.42$; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{N}_3\text{O}$: 288.1138; found: 288.1142.

3-(2-Hydroxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4n). Off white solid; MP 228-230 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.02$ (t, $J = 6.8$ Hz, 1H), 7.11 (t, $J = 7.6$ Hz, 1H), 7.28 (distorted t, $J = 8.4, 6.4$ Hz, 1H), 7.39-7.47 (m, 2H), 7.79 (d, $J = 7.6$ Hz, 1H), 7.91 (d, $J = 9.2$ Hz, 1H), 8.62 (d, $J = 7.2$ Hz, 1H), 10.93 (bs, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 111.54, 114.98, 117.30, 118.34, 119.62, 123.56, 124.68, 127.85, 131.60, 144.98, 149.93, 156.89$; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{10}\text{N}_3\text{O}$: 212.0825; found: 212.0831.

3-(4-*N,N*-Dimethylaminophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4o). White solid; MP 190-192 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 3.03$ (s, 6H), 6.64 (d, $J = 8.8$ Hz, 2H), 7.09 (t, $J = 6.0$ Hz, 1H), 7.72 (t, $J = 7.6$ Hz, 1H), 7.81 (d, $J = 8.4$ Hz, 2H), 8.03 (bs, 1H), 8.30 (d, $J = 3.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 40.12, 111.07, 117.96, 119.17, 121.25, 129.33, 138.05, 147.45, 153.22, 155.89$; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{15}\text{N}_4$: 239.1297; found: 239.1301.

3-(4-*N,N*-Diethylamino-2-hydroxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (4p). Pale yellow solid; MP 218-220 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 1.20$ (t, $J = 7.2$ Hz, 6H), 3.37-3.42 (q, $J = 6.8$ Hz, 4H), 6.34 (d, $J = 8.8$ Hz, 1H), 6.44 (s, 1H), 6.86 (t, $J = 6.8$ Hz, 1H), 7.25 (distorted t, $J = 8.8, 4.4$ Hz, 1H), 7.54 (d, $J = 8.8$ Hz, 1H), 7.76 (d, $J = 8.8$ Hz, 1H), 8.47 (d, $J = 7.2$ Hz, 1H), 11.01 (bs, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 12.73, 44.49, 99.01, 99.31, 103.53, 114.14, 117.07, 123.70, 125.72, 127.10, 145.92, 149.18, 150.21, 158.48$; HRMS (ESI-MS): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{19}\text{N}_4\text{O}$: 283.1560; found: 283.1566.

Conclusion:

We have discovered an efficient and elegant straight forward strategy for the synthesis of triazolopyridine derivatives in good to excellent yields at room temperature from easily available 2-hydrazinopyridine and substituted aromatic aldehydes. A simple open flask reaction operation, use of simple and abundant substrates, wide functional group tolerance, mild conditions and short reaction time are striking features of this reaction. Application of this facile and practical protocol for the selective construction of triazolopyridines scaffold in the complex molecules

bearing more than one active sites and their eventual use in optoelectronic devices is underway in our group.

Notes

The authors declare no competing financial interest.

Acknowledgements

This work was supported by CSIR-New Delhi (sanction no. 01(2427)/10/EMR-II dated 28/12/2010, pool scheme no. 8644-A). K.S.V. thanks UGC-SAP, New Delhi for award of Senior Research Fellowship.

References:

1. G. Jones, *Advances in Heterocyclic Chemistry*, 2002, **83**, 1-70.
2. (a) K. F. McClure, Y. A. Abramov, E. R. Laird, J. T. Barberia, W. Cai, T. J. Carty, S. R. Cortina, D. E. Danley, A. J. Dipesa, K. M. Donahue, M. A. Dombroski, N. C. Elliott, C. A. Gabel, S. Han, T. R. Hynes, P. K. Lemotte, M. N. Mansour, E. S. Marr, M. A. Letavic, J. Pandit, D. B. Ripin, F. J. Sweeney, D. Tan, and Y. Tao, *J. Med. Chem.*, 2005, **48**, 5728–5737; (b) D. Kim, L. Wang, J. J. Hale, C. L. Lynch, R. J. Budhu, M. Maccoss, S. G. Mills, L. Malkowitz, S. L. Gould, J. A. DeMartino, M. S. Springer, D. Hazuda, M. Miller, J. Kessler, R. C. Hrin, G. Carver, A. Carella, K. Henry, J. Lineberger, W. A. Schleif, and E. A. Emini, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2129–2134; (c) L. Savini, L. Chiasserini, C. Pellerano, W. Filippelli, and G. Falcone, *Farm.*, 2001, **56**, 939–945.
3. (a) D. Brown and Y. Iwai, *Aust. J. Chem.*, 1979, **32**, 2727-2733; (b) A. K. Sadana, Y. Mirza, K. R. Aneja, and O. Prakash, *Eur. J. Med. Chem.*, 2003, **38**, 533–536.
4. (a) R. Peignier, A. Chene, R. Cantegril, and J. Mortier, *Eur. Pat. Appl.*, 441718, 1991; (b) R. Sarges, H. R. Howard, R. G. Browne, L. A. Lebel, P. A. Seymour, and B. K. Koe, *J. Med. Chem.*, 1990, **33**, 2240–2254.
5. (a) Y. Yoshimura, K. Tomimatsu, T. Nishimura, A. Miyake, and N. Hashimoto, *J. Antibiot.*, 1992, **45**, 721–734; (b) E. C. Lawson, W. J. Hoekstra, M. F. Addo, P. Andrade-Gordon, B. P. Damiano, J. A. Kauffman, J. A. Mitchell, and B. E. Maryanoff, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 2619–2622; (c) A. S. Kalgutkar, H. L. Hatch, F. Kosea, H. T. Nguyen, E. F. Choo, K. F. McClure, T. J. Taylor, K. R. Henne, A. V Kuperman, M. A. Dombroski, and M. A. Letavic, *Biopharm. Drug Dispos.*, 2006, **27**, 371–386.

6. J. D. Bower and F. P. Doyle, *J. Chem. Soc.*, 1957, 727-732.
7. A. Pollak and M. Tišler, *Tetrahedron*, 1966, **22**, 2073–2079.
8. M. S. Gibson, *Tetrahedron*, 1963, **19**, 1587–1589.
9. Y. Wang, K. Sarris, D. R. Sauer, and S. W. Djuric, *Tetrahedron Lett.*, 2007, **48**, 2237–2240.
10. (a) V. S. Padalkar, V. S. Patil, K. R. Phatangare, P. G. Umape, and N. Sekar, *Synth. Commun.*, 2011, **41**, 925–938; (b) P. Kumar, *Chem. Heterocycl. Compd.*, 2012, **47**, 1237–1243.
11. (a) D. R. Sliskovic, Bicyclic 5-6 Systems with One Ring Junction, Nitrogen Atom: Two Extra Heteroatoms 2: 0. In *Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982-1995: The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds*; A. R. Katritzky, C. W. Rees, E. F. V. Scriven, Eds., Pergamon: Oxford, New York, 1996, Vol. 8, Chapter 13, pp 367-388.
12. M. A. Schmidt and X. Qian, *Tetrahedron Lett.*, 2013, **54**, 5721–5726.
13. O. R. Thiel, M. M. Achmatowicz, A. Reichelt, and R. D. Larsen, *Angew. Chem. Int. Ed.*, 2010, **49**, 8395–8398.
14. A. Reichelt, J. R. Falsey, R. M. Rzasa, O. R. Thiel, M. M. Achmatowicz, R. D. Larsen, and D. Zhang, *Org. Lett.*, 2010, **12**, 792–795.
15. B. Pawar, V. Padalkar, K. Phatangare, S. Nirmalkar, and A. Chaskar, *Catal. Sci. Technol.*, 2011, **1**, 1641-1644.
16. K. Phatangare, V. Padalkar, D. Mhatre, K. Patil, and A. Chaskar, *Synth. Commun.*, 2009, **39**, 4117–4121.
17. S. Takale, S. Parab, K. Phatangare, R. Pisal, and A. Chaskar, *Catal. Sci. Technol.*, 2011, **1**, 1128-1132.
18. S. Takale, J. Patil, V. Padalkar, R. Pisal, and A. Chaskar, *J. Braz. Chem. Soc.*, 2012, **23**, 966–969.